From GlobeNewswire: 2025-06-02 19:30:00

Nxera Pharma Co., Ltd. announces a $15 million payment from partner Neurocrine Biosciences for dosing the first patient in a Phase 3 program of NBI-1117568 as a potential treatment for schizophrenia. The payment will be recognized as revenue in the second quarter of 2025. Neurocrine initiated the Phase 3 study in May 2025, a global trial evaluating NBI-’568 in adults with schizophrenia. The study aims to enroll approximately 280 patients and focuses on reducing symptoms with key endpoints including PANSS and CGI-S scales. Nxera is dedicated to developing innovative medicines globally, employing 400 people across key locations.



Read more at GlobeNewswire: Nxera Pharma to Receive US$15 Million from Neurocrine